共 94 条
[1]
Kerr D(2019)Blastic plasmacytoid dendritic cell neoplasm Curr Treat Options Oncol 20 9-789
[2]
Zhang L(2015)How to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) Patients : results on 86 patients of the French BPDCN Network Blood. 126 23-87
[3]
Sokol L(2017)Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study Br J Haematol 179 781-407
[4]
Poret E(2019)Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pre-targeted therapy benchmark Blood. 134 678-81
[5]
Vidal C(2018)Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Am J Hematol 93 401-9
[6]
Desbrosses Y(2017)Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax Cancer Discov. 7 156-392
[7]
Angelot Delettre F(2017)Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report Medicine (Baltimore). 96 e9452-1637
[8]
Pagadoy M(2019)Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement Haematologica. 104 e222-858
[9]
Pugin A(2018)Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm N Engl J Med. 379 1479-1945
[10]
Kharfan-Dabaja MA(2019)Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: a case-report and review of literature Leukemia Research. 85 106199-undefined